Aducanumab: A Deep Dive into BIIB037 and its Impact This drug, initially known as BIIB037, constitutes a complex attempt to combat mild Alzheimer's disease. Developed by Biogen, the treatment functions by removing https://www.targetmol.com/compound/aducanumab